摘要:
Methods and compositions for reducing chemotherapy and radiotherapy induced emises with 5-HT3 receptor antagonists are disclosed, especially with palonosetron.
摘要:
Methods and compositions for reducing chemotherapy and radiotherapy induced emises with 5-HT3 receptor antagonists are disclosed, especially with palonosetron.
摘要:
Methods are provided to teat post-operative nausea and vomiting, as well as emeses generally, with 5-HT3 receptor antagonists. In particular, the invention discloses methods for reducing post-operative nausea and vomiting and other emetic events with palonosetron.
摘要:
The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
摘要:
The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
摘要:
A process for the preparation of 13-cis-retinoic acid (I) from 3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienyl)-triphenylphosphonium chloride (IIa) and 5-hydroxy-4-methyl-2(5H)-furanone (III) is herein disclosed. Compounds (IIa) and (III) are reacted in ethanol as the solvent and KOH as the base at a temperature ranging from −5 to 0° C. to give a mixture of retinoic acids which is isomerized to (I) by treatment with a palladium complex.
摘要:
The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
摘要:
The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
摘要:
Amorphous and polymorphic of palonosetron hydrochloride are disclosed that can be characterized by X-ray powder diffraction patterns, thermal properties, purity and methods of manufacture. These forms of palonosetron hydrochloride can be produced from solution or by solid state interconversions. The forms can be used in pharmaceutical formulations: particularly preferred uses of these formulations are in prevention and treatment of nausea and emesis arising from chemotherapy or postoperative side effects. The forms can optionally be used as mixtures of the crystalline and/or amorphous forms.
摘要:
A process for the preparation of 13-cis-retinoic acid (I) from 3-methyl-5-(2,6,6-trimethyl-1-cyclohexan-1-yl)-2,4-pentadienyl)-triphenylphosphonium chloride (IIa) and 5-hydroxy-4-methyl-2(5H)-furanone (III) is herein disclosed. Compounds (IIa) and (III) are reacted in ethanol as the solvent and KOH as the base at a temperature ranging from −5 to 0° C. to give a mixture of retinoic acids which is isomerised to (I) by treatment with a palladium complex.